ClinicalTrials.gg
RecruitingNCT07565753TEAPOTUpdated Jul 17, 2026

TEAPOT Study Multisite

An Early Phase 1 interventional study of Tranexamic Acid Injectable Product and Normal Saline in Hemorrhage, Surgical and Tonsillar Bleeding, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 3 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by The University of Texas Health Science Center at San Antonio · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies testing Tranexamic Acid in Blood Loss, Surgical — 9 open to participants now, 9 under way, 4 of them phase 3. Tranexamic Acid · Blood Loss, Surgical.

Planned enrollment
42nd of 46
30 · median 98
Started
2026
with 3 others
Phase 1
6 of 46
4 open now
Registered
43rd of 46
by date
Lead sponsor
2 of 46
The University of Texas Health Science Center at San Antonio

Among the 46 studies testing Tranexamic Acid in Blood Loss, Surgical, this one is the 42nd largest by planned enrollment, is one of 4 that started in 2026, is one of 6 in phase 1, and was the 43rd registered.

Blood Loss, Surgical

213 studies on the registry are indexed under Blood Loss, Surgical; 40 are open to participants now.

Browse Blood Loss, Surgical studies →

Open to participants now

9 of the 46 studies testing Tranexamic Acid in Blood Loss, Surgical are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 27 Blood Loss, Surgical studies recruiting now, 10 (37%) set no upper age limit and 14 (52%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing Tranexamic Acid in Blood Loss, Surgical, or all of them as a file.
02

Study summary

After a child has their tonsils removed, sometimes they might bleed which can be a problem. There is a special mist medicine called nebulized tranexamic acid (TXA) that might help stop the bleeding without having to touch the sore spot. If this mist works well, it could help kids get better by making sure they don't have to go back for more surgery or need blood from someone else. Not having another surgery is good because it means kids won't have to sleep under medicine again, which can sometimes be risky for their brains and breathing, and they won't feel as scared or hurt.

Read the detailed description

The study intervention involves administering nebulized tranexamic acid (TXA) to pediatric patients with traumatic hemorrhage (PTH). The intervention consists of three consecutive doses of nebulized TXA.

The dosage of nebulized TXA is adjusted based on the child's weight. For children weighing more than 25 kg, each dose is 500 mg. For children weighing less than 25 kg, each dose is 250 mg.

Frequency: The three doses of nebulized TXA are administered consecutively over the course of approximately an hour. Administration Method: Nebulized TXA is delivered through a nebulizer device. A nebulizer converts the liquid medication into a fine mist or aerosol, which is then inhaled by the patient. This method allows the medication to be delivered directly to the respiratory tract, where it can exert its effect on the bleeding site. Delivery Setting: The intervention may take place in a clinical setting, such as a hospital or outpatient clinic, where nebulizer devices and medical supervision are readily available. Each patient receives three nebulized independent doses of TXA in succession. The delivery of the intervention is carried out by healthcare professionals trained in administering nebulized medications.

03

Conditions studied

  • Hemorrhage, Surgical
  • Tonsillar Bleeding

Browse trials for

Keywords

  • Tranexamic Acid
  • Nebulizer
  • Post tonsillectomy hemorrhage
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Received a tonsillectomy
  2. Presents to the ED with secondary* post-tonsillectomy hemorrhage
  3. Children between age of 2 to 17 years of age (i.e., before their 18th birthday) *Secondary post-tonsillectomy hemorrhage is defined as greater than 24 hours from their primary tonsillectomy operation (arrival in recovery/PACU).

Exclusion criteria

Exclusion Criteria:

  1. Known and documented bleeding or clotting disorder.
  2. Known pregnancy.
  3. Patients with known or allergic response to tranexamic acid.
  4. Parents or guardians who cannot communicate in English or Spanish.
  5. Intubation prior to enrollment.
  6. Previously enrolled patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Nebulized Tranexamic Acid

    Subjects will be adminstered nebulized TXA post-tonsillectomy if they return to the emergency room with hemorrhage after surgery

    Drug: Tranexamic Acid Injectable Product

  • Placebo comparator
    Nebulized Saline

    Subjects will be adminstered nebulized saline post-tonsillectomy if they return to the emergency room with hemorrhage after surgery

    Other: Normal Saline

Interventions

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive three doses of TXA 500 mg (5 mL of TXA 100mg/ml) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.

    Also known as: TXA 100mg/ml

  • OtherNormal Saline

    Participants will receive three 5 ml doses of placebo (normal saline) nebulized using a PARI LC D Disposable Nebulizer or equivalent over 10-15 minutes using 8 or greater liter/minute of gas flow.

    Also known as: 0.9% saline solution

06

What researchers measure

Primary outcomes

  1. Number of patients enrolled per month

    Assess target enrollment of patients per site per month.

    Time frame: Baseline to 18 months (or duration of study approximately 18 months)

  2. Number of nebulizations per patient

    Evaluate the ability to nebulize at least two doses of TXA to children with PTH

    Time frame: Baseline to 18 months (or duration of study approximately 18 months)

  3. Indirect local concentration of nebulized TXA

    Limited data on nebulized TXA systematic absorption. Topical PK studies of TXA document a significant reduction in systematic levels but the same hemostasis effect. Collection of two blood samples from each participant. This will verify a pulmonary physiological-based PK model (PBPK) (i.e., nasal cavity, pharynx, and lung) that indirectly predicts the oropharyngeal and systematic concentration of nebulized TXA.

    Time frame: Immediately post nebulizer treatment (within 60 minutes) and then within 8 hours.

  4. Systemic Concentration of nebulized TXA

    Pharmacokinetics samples will be collected after completion of the last nebulized treatment received within sixty minutes. A second time point should then be collected after sixty minutes up to eight hours from last nebulization, separated from the previous time point by at least sixty to ninety minutes. The serum TXA levels will be used to verify a TXA Physiological-based Pharmacokinetic model and determine the population variability. This PBPK model is built by our research pharmacist based on extensive research already completed on TXA distribution and metabolism. Once the model is built, the investigators only need a one to two samples to determine if the model accurately reflects collect samples. The investigators will develop a base model to determine a best-fit compartmental model, distribution, and elimination kinetics. The investigators will also use stochastic models to evaluate between-subject variability in PK parameters.

    Time frame: Immediately post nebulizer treatment (within 60 minutes) and up to eights hours.

Secondary outcomes

  1. Number of return visits to the OR

    The need for return to the Operating Room (OR) for surgical management of PTH) will be followed for up to seven days after randomization

    Time frame: Baseline to 18 months (or duration of study approximately 18 months)

  2. Estimated blood loss

    Determine the estimated blood loss per participant

    Time frame: Baseline to 7 days

  3. Number of recurrences of PTH

    Number of participants in which there was a recurrence of post-tonsillectomy hemorrhage after the study drug was administered

    Time frame: Baseline to 18 months (or duration of study approximately 18 months)

  4. Number of blood transfusions required

    Blood product transfusion volume will be measured at discharge or 24 hours (whichever comes first). This will include the volume of packed red blood cells, platelets, plasma, cryoprecipitate, or whole blood. Any mention of blood loss in electronic health records from emergency, anesthesiology, or surgeons' notes will be recorded.

    Time frame: Baseline to 18 months (or duration of study approximately 18 months)

Other outcomes

  1. Wong-Baker FACES Pain Rating Scale or FLACC (Face, Legs, Activity, Cry, Consolability) Score

    Admission of this pain scale will be age dependent, but yields the same score for the patient selection of pain or the visual cues available for pain assessment by the study team. Wong-Baker FACES Pain scale: The participant rates their pain from 0=No hurt to 10=Hurts worst, with a higher score indicating greater pain. FLACC Score: Scores 5 items from 0-2 with a total possible score of 10. A higher score indicates more pain.

    Time frame: Day 7 after randomization (plus or minus one day)

  2. Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety scale for Adults

    The PROMIS Anxiety Short Form 8a is scored by summing responses to 8 items, each rated on a 5-point scale (1=Never to 5=Always) over the past 7 days, resulting in a raw score range of 8 to 40. Higher scores indicate greater anxiety severity.

    Time frame: Day 7 after randomization (plus or minus one day)

  3. Patient Reported Outcomes Measurement Information System (PROMIS) Anxiety scale for Children

    The PROMIS Anxiety Short Form 8a is scored by summing responses to 8 items, each rated on a 5-point scale (1=Never to 5=Always) over the past 7 days, resulting in a raw score range of 8 to 40. Higher scores indicate greater anxiety severity.

    Time frame: Day 7 after randomization(plus or minus one day)

07

Study locations

1 of 3 sites recruiting
  • University of California at Davis Medical Center
    Davis, California 95819, United States
    Recruiting
  • Hasbro Childrens' Hospital
    Providence, Rhode Island 02903, United States
    Not yet recruiting
  • University Hospital
    San Antonio, Texas 78229, United States
    Not yet recruiting
08

References and documents

Publications

  • Meyer AD, Schwarz W, Erwin D, Earley M, Yellepeddi VK, Chun TH, Casper TC, Nishijima DK. TranExamic Atomized for Pediatric post-Operative Tonsillectomy hemorrhage (TEAPOT): Study protocol for a pilot randomized controlled trial. PLoS One. 2026 Jul 28;21(7):e0353841. doi: 10.1371/journal.pone.0353841. eCollection 2026. PubMed 42520054 ↗

Individual participant data

Plan to share: Yes — This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results in Information Submission rule. As such, this trial will be registered at ClinicalTrials.gov, and results in information from this trial will be submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-reviewed journals.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data from this study may be requested by other researchers 3 years after the completion of the primary endpoint by contacting Andrew D. Meyer, MD, MS or through the DCC public use dataset website.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Sep 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2026
First posted
May 4, 2026
StartActual
Jul 14, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Sep 30, 2028
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07565753
Responsible party
Andrew D. Meyer (Associate Professor, The University of Texas Health Science Center at San Antonio) — Principal investigator
First posted
May 4, 2026
Start date
Jul 14, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Jul 17, 2026

Study contacts

Andrew D Meyer, MD, MS
Contact
meyera@uthscsa.edu
210-567-4424
Stephanie Perez, MHA
Contact
perezs11@uthscsa.edu
(210) 450-8973
Andrew D Meyer, MD, MS
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion